Akari Therapeutics

Ticker

AKTX

Website

Sector

Biotech

Tearsheet

Why Invest

Test Lead drug, first in class, differentiated bifunctional mechanism of action. Positive clinical and safety data – with two open Phase 3 clinical studies. Development pipeline – large markets with partnering upside.

  

  1. Specialty pharma play in autoimmune/anti-inflammatory. Has a strong balance sheet with a debt ratio of .91 with increasing asset growth and decreasing debt